Literature DB >> 30536431

Immunoglobulins and virus antibody titers: of past needs, current requirements, and future options.

Thomas R Kreil1, Maria R Farcet1.   

Abstract

BACKGROUND: Immunoglobulins (Igs) have been in clinical use for almost 70 years, and early on were also used in conjunction with exposure to the measles virus or polio virus. The US regulations that describe functional Ig lot release thus require the demonstration of minimum antibody titers against these two viruses, although the use of vaccines has now dramatically reduced their incidence. The lower clinical importance of these viruses raises the question of whether other virus antibodies might be more informative for patients with immunodeficiency. STUDY DESIGN AND METHODS: A literature survey was conducted to identify viruses of potential clinical concern for people with immunodeficiency. The viruses selected have stable seroepidemiology and associated functional antibody assays. As a result, neutralizing antibody titers to human adenovirus 5 (HAdV5), respiratory syncytial virus (RSV) serotypes A and B, and human parainfluenza virus 3 (hPIV3) were determined in Ig lots produced from plasma collected in either the United States or the European Union.
RESULTS: The virus antibody titers measured were high and consistent among the Ig lots tested. Use of either US- or EU-derived plasma as starting material resulted in equivalent virus antibody titers, with the exception of RSV serotype B, for which a lower titer was seen in EU plasma-derived Ig lots.
CONCLUSION: With the significant decline in measles virus and polio virus circulation, and even their potential eradication, measurement of antibody titers against other viruses in Ig products may be more informative for functional lot release testing.
© 2018 AABB.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30536431     DOI: 10.1111/trf.15016

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

Review 1.  COVID-19: what has been learned and to be learned about the novel coronavirus disease.

Authors:  Ye Yi; Philip N P Lagniton; Sen Ye; Enqin Li; Ren-He Xu
Journal:  Int J Biol Sci       Date:  2020-03-15       Impact factor: 6.580

2.  In silico designing of multi-epitope vaccine construct against human coronavirus infections.

Authors:  Arpita Devi; Nyshadham S N Chaitanya
Journal:  J Biomol Struct Dyn       Date:  2020-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.